Neuroscience Education Institute

Neuroscience Education Institute NEI is the preeminent provider of continuing education and practice-based tools for healthcare professionals who treat patients with mental health disorders.

Thousands of clinicians consider NEI their top mental health resource for point of care answers and continuing medical education (CME). Here's why:

NEI Prescribe, our prescribing app, features over 150 psychiatric medications and has a dedicated Child and Adolescent section with in-depth coverage of the most commonly prescribed psychotropic drugs in pediatric patients. Continuously updated and wi

th an interactive filter to search for medications based on key drug interactions and side effects, NEI Prescribe is your tool for point of care prescribing. Our two annual conferences—NEI Congress in the fall and NEI Synapse in the spring—fuse learning, quality, and entertainment into an educational experience that will empower you to provide the best possible care for your patients. We offer hundreds of online CME activities, including animations, case studies, self-assessments, and encore presentations from NEI's live events. The Master Psychopharmacology Program is an online assessment-based certificate program designed to help clinicians develop proficiency in the practice of psychopharmacology. Create a free NEI account at http://nei.global to take advantage of these resources. NEI Membership is required to access the full spectrum of resources, including the Master Psychopharmacology Program. Learn more at http://nei.global/mbroverview. Neuroscience Education Institute, An HMP Global Company

05/01/2026

Dr. Jeffrey Strawn reviews benzodiazepines for insomnia

05/01/2026

For the next three days, you’re surrounded by clinicians who share one goal: improving patient outcomes through better care.

Welcome to the 2026 NEI Spring Congress! ✨

05/01/2026

The energy is high here in Florida! 🌴 NEI Spring Congress Chair, Dr. Roger McIntyre, sets the stage for three days of learning focused on advancing psychiatry and psychopharmacology. Whether you’re joining us in person or virtually, welcome to meaningful conversations, fresh insights, and impactful learning!

The U.S. Food and Drug Administration has approved oral dextromethorphan-bupropion for the treatment of agitation associ...
04/30/2026

The U.S. Food and Drug Administration has approved oral dextromethorphan-bupropion for the treatment of agitation associated with Alzheimer disease. Read more:

The U.S. Food and Drug Administration has approved oral dextromethorphan-bupropion for the treatment of agitation associated with Alzheimer disease.

Psychotropic polypharmacy is common, but clear guidance on when to stop medications has been lacking. A new internationa...
04/29/2026

Psychotropic polypharmacy is common, but clear guidance on when to stop medications has been lacking. A new international consensus offers practical direction on when and how to deprescribe. Read more

Psychotropic polypharmacy is common, but clear guidance on when to stop medications has been lacking. A new international consensus offers practical direction on when and how to deprescribe.

Bring NEI Spring Congress to you. Access world-class psychiatric education and practical insights from anywhere. Join vi...
04/27/2026

Bring NEI Spring Congress to you. Access world-class psychiatric education and practical insights from anywhere. Join virtually to watch expert sessions, engage in live Q&A, and earn CME/CE credit in real time. Register today at

Get full access to expert-led sessions, practical psychopharmacology insights, and real-world strategies you can apply right away.

04/25/2026

highlights the importance of evidence-based treatment for alcohol use disorder. Naltrexone and acamprosate offer distinct mechanisms to reduce cravings and support abstinence, with treatment decisions guided by patient goals and clinical context. Learn how these therapies fit into comprehensive care.

04/23/2026

From Pavlov’s bell to modern GLP-1 therapies, the science of conditioning and neurobiology continues to shape how we understand substance use. Disruptions in reward learning are central to current models of substance use disorders. Dr. Roger McIntyre provides a historical perspective, connecting early conditioning research to the discovery of incretin hormones, including GLP-1, now under investigation for their role in modulating reward pathways.

In this episode, Dr. Andy Cutler sits down with Dr. Thomas Schwartz to unpack insomnia linked to antidepressant disconti...
04/22/2026

In this episode, Dr. Andy Cutler sits down with Dr. Thomas Schwartz to unpack insomnia linked to antidepressant discontinuation. They explore why rebound and withdrawal symptoms can appear during tapering, how to tell discontinuation-related insomnia from relapse or primary sleep disorders, and share practical, evidence-informed strategies for safer tapering and better sleep management in clinical practice. Listen now

In this episode, Dr. Andy Cutler speaks with Dr. Thomas Schwartz about insomnia related to antidepressant discontinuation, including how rebound and withdrawal symptoms can emerge when tapering or stopping treatment.

It’s Saturday morning. ☀️ Log in now to join Drs. Jeffrey Strawn and Karl Doghramji as they explore the intersection of ...
04/18/2026

It’s Saturday morning. ☀️ Log in now to join Drs. Jeffrey Strawn and Karl Doghramji as they explore the intersection of sleep regulation and wellness in mental health care. Not registered yet? There’s still time. Registration is free but required:

Join Drs. Jeffrey Strawn and Karl Doghramji to learn about the intersection of sleep regulation and wellness through three expert-led sessions for mental health clinicians.

Join us this Saturday, April 18, for a free half-day CME/CE program on sleep and mental health. Learn to identify and tr...
04/17/2026

Join us this Saturday, April 18, for a free half-day CME/CE program on sleep and mental health. Learn to identify and treat hypersomnia, narcolepsy, and insomnia, and gain practical strategies to improve patient outcomes.
Save your spot today ➡️

Register for this free half-day CME program on sleep and mental health. Learn how to identify and treat conditions like hypersomnia, narcolepsy, and insomnia, and gain practical strategies to improve patient outcomes.

Posttraumatic stress disorder (PTSD) remains a chronic, often disabling condition, and current first-line treatments lik...
04/17/2026

Posttraumatic stress disorder (PTSD) remains a chronic, often disabling condition, and current first-line treatments like SSRIs can fall short with slow onset and limited efficacy. A novel agent, TSND-201 (methylone), is drawing attention as a potential rapid-acting option. Read more

Posttraumatic stress disorder (PTSD) remains a chronic, often disabling condition, and current first-line treatments like SSRIs can fall short with slow onset and limited efficacy. A novel agent, TSND-201 (methylone), is drawing attention as a potential rapid-acting option

Address

Malvern, PA

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Neuroscience Education Institute posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Neuroscience Education Institute:

Shortcuts

Share

Category